Novel polymorphs of Voxelotor and their processes for preparation thereof

The present invention relates to novel polymorphs of Voxelotor of formula-1, which is represented by the following structural formula-1 and process for preparation thereof. Formula-1

A process for the preparation of 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl] phenoxy}-N-(propan-2-yl) acetamide and its salts

The present application relates to a process for the preparation of 2-{3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy}-N-(propan-2-yl) acetamide represented by the following structural formula-1, which is referred to as Belumosudil and its intermediate preparation thereof. Formula-1. The present application also relates to novel crystalline forms of Belumosudil, its mesylate and its intermediate and preparation thereof

Process for the preparation of 2-[[4-[(7-Chloro-4-quinolyl)amino] pentyl]ethylamino]ethanol sulphate

A process for the preparation of 2-[[4-[(7-Chloro-4-quinolyl)amino]pentyl] ethylamino]ethanol sulfate of compound of Formula-I, which is represented by the following structural formula. Formula-

Process for the preparation of 2-ethoxy-phenol

The present disclosure provides an improved process for the preparation of 2-ethoxy-phenol with reproducibly in good purity and yield

Novel process for the preparation of methyl N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-3­ (methanesulfonamido)phenyl]-1-(propan-2-yl)-1H-pyrazol-4-yl}pyrimidin-2-yl)amino] propan-2­yl}carbamate

Abstract: The present invention relates to a novel process for the preparation of methyl N-{(2S)-1-[(4-{3-[5-chloro-2-fluoro-3­(methanesulfonamido)phenyl]-1-(propan-2-yl)-1H-pyrazol-4-yl}pyrimidin-2-yl)amino]propan-2­yl}carbamate represented by the following structural formula. Formula-1 The present invention also relates to amorphous Encorafenib and amorphous solid dispersions of Encorafenib

Solid state forms of Apalutamide and their process for the preparation thereof

The present disclosure relates to an amorphous solid dispersion comprising Apalutamide of formula-1 and HPMC-AS; process for the preparation thereof. Formula-

Improved process for the preparation of 1-((4-fluorophenyl)carbamoyl) cyclopropanecarboxylic acid

Abstract: Improved process for the preparation of 1-((4-fluorophenyl)carbamoyl) cyclopropanecarboxylic acid of formula-1, which is represented by the following structural formula: which is key intermediate for the preparation of Cabozantinib (S)-malate, which is chemically known as N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N’-(4­fluorophenyl) cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate

Solid state forms of Apalutamide and their process for the preparation thereof

The present disclosure relates to an amorphous solid dispersion comprising Apalutamide of formula-1 and HPMC-E5 and process for the preparation thereof

Novel polymorphs of Lorlatinib and their processes for the preparation thereof

The present invention provides novel polymorphs of Lorlatinib and their processes for the preparation thereo

Process for the preparation of Tenofovir Alafenamide Monofumarate

The present disclosure provides an improved process for the preparation of Tenofovir alafenamide monofumarate with reproducibly in good purity and yield